Reviewer's report

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Version: 5 Date: 15 April 2013

Reviewer: Mark S Fineman

Reviewer's report:

The authors have satisfactorily addressed all of the points raised in the previous reviews.

Major Compulsory Revisions: None

Minor Essential Revisions: None

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.